Global Neurokinin Receptor Antagonists Market Growth 2026-2032
The global Neurokinin Receptor Antagonists market size is predicted to grow from US$ 1429 million in 2025 to US$ 2298 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.
Neurokinin receptor antagonists are an innovative class of oral small-molecule drugs used to prevent and treat postoperative and chemotherapy-induced nausea and vomiting, selectively blocking neurokinin receptors such as substance P and neurokinin B to reduce the transmission of vomiting signals. Their production relies on high-purity active pharmaceutical ingredients (APIs) and key chemical intermediates. Upstream raw materials primarily include amino acid derivatives and organic small-molecule precursors, supplied by companies such as Lonza and Evonik. Formulation manufacturers convert these materials into final oral tablets or capsules through precise synthesis processes to ensure stability and bioavailability. In 2024, global sales of neurokinin receptor antagonists reached 6.03 million boxes, with an average price of 225 USD per box, an average gross margin of 41.5%, and a single production line annual capacity of 300,000 boxes.
Regional Market Landscape
The global market for neurokinin receptor antagonists is primarily concentrated in North America, Europe, and the Asia-Pacific region, with North America holding 60% of the market share, Europe 25%, and Asia-Pacific 15%. North America leads due to mature healthcare systems for managing postoperative nausea and vomiting and cancer-related treatments. Europe demonstrates stable growth with emphasis on drug safety and clinical guideline compliance, while the Asia-Pacific region is gradually expanding, particularly in Japan, South Korea, and China, where demand for high-end antiemetic medications is increasing.
Key Manufacturers and Industry Competition
The main manufacturers include the original developers and their licensed production partners, with the market dominated by a few innovative pharmaceutical companies. Upstream activities involve active pharmaceutical ingredient suppliers and chemical intermediate producers, while downstream covers formulation manufacturing, packaging, and distribution networks. Leading companies hold strong bargaining power and channel advantages. Competition focuses on clinical efficacy, patient adherence, long-term safety, and production cost management, while new entrants must invest heavily in R&D, clinical trials, and regulatory approvals to enter the market.
Technological Trends and Innovation Directions
Technological trends focus on mechanism-targeted optimization, oral sustained-release formulations, and integration with multimodal therapeutic strategies. Innovations aim to improve absorption, tolerability, and individualized dosing, while exploring combination therapies with other antiemetic or anticancer drugs to enhance efficacy and reduce side effects. Advances in formulation processes and drug delivery technologies are key competitive differentiators.
Policy and Industry Development Drivers
Market development is driven by updates in management guidelines for chronic diseases and postoperative nausea and vomiting, health insurance coverage, drug approval systems, and increased awareness of safe and effective novel medications. Regulatory policies on drug safety and rational use significantly influence market dynamics while guiding innovation investment and corporate strategies.
Future Outlook
Neurokinin receptor antagonists are expected to maintain steady growth in the global antiemetic and related treatment market, with North America and Europe continuing to provide primary sales contributions. The Asia-Pacific region will become a key focus for new sales and market expansion. As technological optimization, combination therapy strategies, and insurance coverage advance, the clinical application and patient base are projected to expand, with industry competition becoming more concentrated and market structure stabilizing.
LP Information, Inc. (LPI) ' newest research report, the “Neurokinin Receptor Antagonists Industry Forecast” looks at past sales and reviews total world Neurokinin Receptor Antagonists sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurokinin Receptor Antagonists sales for 2026 through 2032. With Neurokinin Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurokinin Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global Neurokinin Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurokinin Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurokinin Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurokinin Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurokinin Receptor Antagonists.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurokinin Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Neurokinin Receptor Antagonists market?
What factors are driving Neurokinin Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurokinin Receptor Antagonists market opportunities vary by end market size?
How does Neurokinin Receptor Antagonists break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
Neurokinin receptor antagonists are an innovative class of oral small-molecule drugs used to prevent and treat postoperative and chemotherapy-induced nausea and vomiting, selectively blocking neurokinin receptors such as substance P and neurokinin B to reduce the transmission of vomiting signals. Their production relies on high-purity active pharmaceutical ingredients (APIs) and key chemical intermediates. Upstream raw materials primarily include amino acid derivatives and organic small-molecule precursors, supplied by companies such as Lonza and Evonik. Formulation manufacturers convert these materials into final oral tablets or capsules through precise synthesis processes to ensure stability and bioavailability. In 2024, global sales of neurokinin receptor antagonists reached 6.03 million boxes, with an average price of 225 USD per box, an average gross margin of 41.5%, and a single production line annual capacity of 300,000 boxes.
Regional Market Landscape
The global market for neurokinin receptor antagonists is primarily concentrated in North America, Europe, and the Asia-Pacific region, with North America holding 60% of the market share, Europe 25%, and Asia-Pacific 15%. North America leads due to mature healthcare systems for managing postoperative nausea and vomiting and cancer-related treatments. Europe demonstrates stable growth with emphasis on drug safety and clinical guideline compliance, while the Asia-Pacific region is gradually expanding, particularly in Japan, South Korea, and China, where demand for high-end antiemetic medications is increasing.
Key Manufacturers and Industry Competition
The main manufacturers include the original developers and their licensed production partners, with the market dominated by a few innovative pharmaceutical companies. Upstream activities involve active pharmaceutical ingredient suppliers and chemical intermediate producers, while downstream covers formulation manufacturing, packaging, and distribution networks. Leading companies hold strong bargaining power and channel advantages. Competition focuses on clinical efficacy, patient adherence, long-term safety, and production cost management, while new entrants must invest heavily in R&D, clinical trials, and regulatory approvals to enter the market.
Technological Trends and Innovation Directions
Technological trends focus on mechanism-targeted optimization, oral sustained-release formulations, and integration with multimodal therapeutic strategies. Innovations aim to improve absorption, tolerability, and individualized dosing, while exploring combination therapies with other antiemetic or anticancer drugs to enhance efficacy and reduce side effects. Advances in formulation processes and drug delivery technologies are key competitive differentiators.
Policy and Industry Development Drivers
Market development is driven by updates in management guidelines for chronic diseases and postoperative nausea and vomiting, health insurance coverage, drug approval systems, and increased awareness of safe and effective novel medications. Regulatory policies on drug safety and rational use significantly influence market dynamics while guiding innovation investment and corporate strategies.
Future Outlook
Neurokinin receptor antagonists are expected to maintain steady growth in the global antiemetic and related treatment market, with North America and Europe continuing to provide primary sales contributions. The Asia-Pacific region will become a key focus for new sales and market expansion. As technological optimization, combination therapy strategies, and insurance coverage advance, the clinical application and patient base are projected to expand, with industry competition becoming more concentrated and market structure stabilizing.
LP Information, Inc. (LPI) ' newest research report, the “Neurokinin Receptor Antagonists Industry Forecast” looks at past sales and reviews total world Neurokinin Receptor Antagonists sales in 2025, providing a comprehensive analysis by region and market sector of projected Neurokinin Receptor Antagonists sales for 2026 through 2032. With Neurokinin Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurokinin Receptor Antagonists industry.
This Insight Report provides a comprehensive analysis of the global Neurokinin Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurokinin Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurokinin Receptor Antagonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurokinin Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurokinin Receptor Antagonists.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurokinin Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- NK-1 Receptor Antagonists
- NK-3 Receptor Antagonists
- Others
- Vasomotor Symptoms
- Nausea and Vomiting
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma
- Bayer
- Merck
- Heron Therapeutics
- TerSera Therapeutics
- Helsinn Healthcare
- Zoetis
What is the 10-year outlook for the global Neurokinin Receptor Antagonists market?
What factors are driving Neurokinin Receptor Antagonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurokinin Receptor Antagonists market opportunities vary by end market size?
How does Neurokinin Receptor Antagonists break out by Type, by Application?
The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurokinin Receptor Antagonists Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neurokinin Receptor Antagonists by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neurokinin Receptor Antagonists by Country/Region, 2021, 2025 & 2032
2.2 Neurokinin Receptor Antagonists Segment by Type
2.2.1 NK-1 Receptor Antagonists
2.2.2 NK-3 Receptor Antagonists
2.2.3 Others
2.2.4 Neurokinin Receptor Antagonists Sales by Type
2.2.4.1 Global Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
2.2.4.2 Global Neurokinin Receptor Antagonists Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Neurokinin Receptor Antagonists Sale Price by Type (2021-2026)
2.3 Neurokinin Receptor Antagonists Segment by Application
2.3.1 Vasomotor Symptoms
2.3.2 Nausea and Vomiting
2.3.3 Others
2.3.4 Neurokinin Receptor Antagonists Sales by Application
2.3.4.1 Global Neurokinin Receptor Antagonists Sale Market Share by Application (2021-2026)
2.3.4.2 Global Neurokinin Receptor Antagonists Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Neurokinin Receptor Antagonists Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neurokinin Receptor Antagonists Breakdown Data by Company
3.1.1 Global Neurokinin Receptor Antagonists Annual Sales by Company (2021-2026)
3.1.2 Global Neurokinin Receptor Antagonists Sales Market Share by Company (2021-2026)
3.2 Global Neurokinin Receptor Antagonists Annual Revenue by Company (2021-2026)
3.2.1 Global Neurokinin Receptor Antagonists Revenue by Company (2021-2026)
3.2.2 Global Neurokinin Receptor Antagonists Revenue Market Share by Company (2021-2026)
3.3 Global Neurokinin Receptor Antagonists Sale Price by Company
3.4 Key Manufacturers Neurokinin Receptor Antagonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurokinin Receptor Antagonists Product Location Distribution
3.4.2 Players Neurokinin Receptor Antagonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
4.1 World Historic Neurokinin Receptor Antagonists Market Size by Geographic Region (2021-2026)
4.1.1 Global Neurokinin Receptor Antagonists Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neurokinin Receptor Antagonists Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neurokinin Receptor Antagonists Market Size by Country/Region (2021-2026)
4.2.1 Global Neurokinin Receptor Antagonists Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neurokinin Receptor Antagonists Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neurokinin Receptor Antagonists Sales Growth
4.4 APAC Neurokinin Receptor Antagonists Sales Growth
4.5 Europe Neurokinin Receptor Antagonists Sales Growth
4.6 Middle East & Africa Neurokinin Receptor Antagonists Sales Growth
5 AMERICAS
5.1 Americas Neurokinin Receptor Antagonists Sales by Country
5.1.1 Americas Neurokinin Receptor Antagonists Sales by Country (2021-2026)
5.1.2 Americas Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
5.2 Americas Neurokinin Receptor Antagonists Sales by Type (2021-2026)
5.3 Americas Neurokinin Receptor Antagonists Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurokinin Receptor Antagonists Sales by Region
6.1.1 APAC Neurokinin Receptor Antagonists Sales by Region (2021-2026)
6.1.2 APAC Neurokinin Receptor Antagonists Revenue by Region (2021-2026)
6.2 APAC Neurokinin Receptor Antagonists Sales by Type (2021-2026)
6.3 APAC Neurokinin Receptor Antagonists Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurokinin Receptor Antagonists by Country
7.1.1 Europe Neurokinin Receptor Antagonists Sales by Country (2021-2026)
7.1.2 Europe Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
7.2 Europe Neurokinin Receptor Antagonists Sales by Type (2021-2026)
7.3 Europe Neurokinin Receptor Antagonists Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurokinin Receptor Antagonists by Country
8.1.1 Middle East & Africa Neurokinin Receptor Antagonists Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
8.2 Middle East & Africa Neurokinin Receptor Antagonists Sales by Type (2021-2026)
8.3 Middle East & Africa Neurokinin Receptor Antagonists Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists
10.3 Manufacturing Process Analysis of Neurokinin Receptor Antagonists
10.4 Industry Chain Structure of Neurokinin Receptor Antagonists
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurokinin Receptor Antagonists Distributors
11.3 Neurokinin Receptor Antagonists Customer
12 WORLD FORECAST REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
12.1 Global Neurokinin Receptor Antagonists Market Size Forecast by Region
12.1.1 Global Neurokinin Receptor Antagonists Forecast by Region (2027-2032)
12.1.2 Global Neurokinin Receptor Antagonists Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neurokinin Receptor Antagonists Forecast by Type (2027-2032)
12.7 Global Neurokinin Receptor Antagonists Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.1.3 Astellas Pharma Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.2.3 Bayer Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.3.3 Merck Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Heron Therapeutics
13.4.1 Heron Therapeutics Company Information
13.4.2 Heron Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.4.3 Heron Therapeutics Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Heron Therapeutics Main Business Overview
13.4.5 Heron Therapeutics Latest Developments
13.5 TerSera Therapeutics
13.5.1 TerSera Therapeutics Company Information
13.5.2 TerSera Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.5.3 TerSera Therapeutics Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 TerSera Therapeutics Main Business Overview
13.5.5 TerSera Therapeutics Latest Developments
13.6 Helsinn Healthcare
13.6.1 Helsinn Healthcare Company Information
13.6.2 Helsinn Healthcare Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.6.3 Helsinn Healthcare Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Helsinn Healthcare Main Business Overview
13.6.5 Helsinn Healthcare Latest Developments
13.7 Zoetis
13.7.1 Zoetis Company Information
13.7.2 Zoetis Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.7.3 Zoetis Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zoetis Main Business Overview
13.7.5 Zoetis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurokinin Receptor Antagonists Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Neurokinin Receptor Antagonists by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Neurokinin Receptor Antagonists by Country/Region, 2021, 2025 & 2032
2.2 Neurokinin Receptor Antagonists Segment by Type
2.2.1 NK-1 Receptor Antagonists
2.2.2 NK-3 Receptor Antagonists
2.2.3 Others
2.2.4 Neurokinin Receptor Antagonists Sales by Type
2.2.4.1 Global Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
2.2.4.2 Global Neurokinin Receptor Antagonists Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Neurokinin Receptor Antagonists Sale Price by Type (2021-2026)
2.3 Neurokinin Receptor Antagonists Segment by Application
2.3.1 Vasomotor Symptoms
2.3.2 Nausea and Vomiting
2.3.3 Others
2.3.4 Neurokinin Receptor Antagonists Sales by Application
2.3.4.1 Global Neurokinin Receptor Antagonists Sale Market Share by Application (2021-2026)
2.3.4.2 Global Neurokinin Receptor Antagonists Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Neurokinin Receptor Antagonists Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Neurokinin Receptor Antagonists Breakdown Data by Company
3.1.1 Global Neurokinin Receptor Antagonists Annual Sales by Company (2021-2026)
3.1.2 Global Neurokinin Receptor Antagonists Sales Market Share by Company (2021-2026)
3.2 Global Neurokinin Receptor Antagonists Annual Revenue by Company (2021-2026)
3.2.1 Global Neurokinin Receptor Antagonists Revenue by Company (2021-2026)
3.2.2 Global Neurokinin Receptor Antagonists Revenue Market Share by Company (2021-2026)
3.3 Global Neurokinin Receptor Antagonists Sale Price by Company
3.4 Key Manufacturers Neurokinin Receptor Antagonists Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurokinin Receptor Antagonists Product Location Distribution
3.4.2 Players Neurokinin Receptor Antagonists Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
4.1 World Historic Neurokinin Receptor Antagonists Market Size by Geographic Region (2021-2026)
4.1.1 Global Neurokinin Receptor Antagonists Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Neurokinin Receptor Antagonists Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Neurokinin Receptor Antagonists Market Size by Country/Region (2021-2026)
4.2.1 Global Neurokinin Receptor Antagonists Annual Sales by Country/Region (2021-2026)
4.2.2 Global Neurokinin Receptor Antagonists Annual Revenue by Country/Region (2021-2026)
4.3 Americas Neurokinin Receptor Antagonists Sales Growth
4.4 APAC Neurokinin Receptor Antagonists Sales Growth
4.5 Europe Neurokinin Receptor Antagonists Sales Growth
4.6 Middle East & Africa Neurokinin Receptor Antagonists Sales Growth
5 AMERICAS
5.1 Americas Neurokinin Receptor Antagonists Sales by Country
5.1.1 Americas Neurokinin Receptor Antagonists Sales by Country (2021-2026)
5.1.2 Americas Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
5.2 Americas Neurokinin Receptor Antagonists Sales by Type (2021-2026)
5.3 Americas Neurokinin Receptor Antagonists Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurokinin Receptor Antagonists Sales by Region
6.1.1 APAC Neurokinin Receptor Antagonists Sales by Region (2021-2026)
6.1.2 APAC Neurokinin Receptor Antagonists Revenue by Region (2021-2026)
6.2 APAC Neurokinin Receptor Antagonists Sales by Type (2021-2026)
6.3 APAC Neurokinin Receptor Antagonists Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurokinin Receptor Antagonists by Country
7.1.1 Europe Neurokinin Receptor Antagonists Sales by Country (2021-2026)
7.1.2 Europe Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
7.2 Europe Neurokinin Receptor Antagonists Sales by Type (2021-2026)
7.3 Europe Neurokinin Receptor Antagonists Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurokinin Receptor Antagonists by Country
8.1.1 Middle East & Africa Neurokinin Receptor Antagonists Sales by Country (2021-2026)
8.1.2 Middle East & Africa Neurokinin Receptor Antagonists Revenue by Country (2021-2026)
8.2 Middle East & Africa Neurokinin Receptor Antagonists Sales by Type (2021-2026)
8.3 Middle East & Africa Neurokinin Receptor Antagonists Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists
10.3 Manufacturing Process Analysis of Neurokinin Receptor Antagonists
10.4 Industry Chain Structure of Neurokinin Receptor Antagonists
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurokinin Receptor Antagonists Distributors
11.3 Neurokinin Receptor Antagonists Customer
12 WORLD FORECAST REVIEW FOR NEUROKININ RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION
12.1 Global Neurokinin Receptor Antagonists Market Size Forecast by Region
12.1.1 Global Neurokinin Receptor Antagonists Forecast by Region (2027-2032)
12.1.2 Global Neurokinin Receptor Antagonists Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Neurokinin Receptor Antagonists Forecast by Type (2027-2032)
12.7 Global Neurokinin Receptor Antagonists Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.1.3 Astellas Pharma Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.2.3 Bayer Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.3.3 Merck Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Heron Therapeutics
13.4.1 Heron Therapeutics Company Information
13.4.2 Heron Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.4.3 Heron Therapeutics Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Heron Therapeutics Main Business Overview
13.4.5 Heron Therapeutics Latest Developments
13.5 TerSera Therapeutics
13.5.1 TerSera Therapeutics Company Information
13.5.2 TerSera Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.5.3 TerSera Therapeutics Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 TerSera Therapeutics Main Business Overview
13.5.5 TerSera Therapeutics Latest Developments
13.6 Helsinn Healthcare
13.6.1 Helsinn Healthcare Company Information
13.6.2 Helsinn Healthcare Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.6.3 Helsinn Healthcare Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Helsinn Healthcare Main Business Overview
13.6.5 Helsinn Healthcare Latest Developments
13.7 Zoetis
13.7.1 Zoetis Company Information
13.7.2 Zoetis Neurokinin Receptor Antagonists Product Portfolios and Specifications
13.7.3 Zoetis Neurokinin Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zoetis Main Business Overview
13.7.5 Zoetis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neurokinin Receptor Antagonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neurokinin Receptor Antagonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NK-1 Receptor Antagonists
Table 4. Major Players of NK-3 Receptor Antagonists
Table 5. Major Players of Others
Table 6. Global Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 7. Global Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Table 8. Global Neurokinin Receptor Antagonists Revenue by Type (2021-2026) & ($ million)
Table 9. Global Neurokinin Receptor Antagonists Revenue Market Share by Type (2021-2026)
Table 10. Global Neurokinin Receptor Antagonists Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Neurokinin Receptor Antagonists Sale by Application (2021-2026) & (K Units)
Table 12. Global Neurokinin Receptor Antagonists Sale Market Share by Application (2021-2026)
Table 13. Global Neurokinin Receptor Antagonists Revenue by Application (2021-2026) & ($ million)
Table 14. Global Neurokinin Receptor Antagonists Revenue Market Share by Application (2021-2026)
Table 15. Global Neurokinin Receptor Antagonists Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Neurokinin Receptor Antagonists Sales by Company (2021-2026) & (K Units)
Table 17. Global Neurokinin Receptor Antagonists Sales Market Share by Company (2021-2026)
Table 18. Global Neurokinin Receptor Antagonists Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Neurokinin Receptor Antagonists Revenue Market Share by Company (2021-2026)
Table 20. Global Neurokinin Receptor Antagonists Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Neurokinin Receptor Antagonists Producing Area Distribution and Sales Area
Table 22. Players Neurokinin Receptor Antagonists Products Offered
Table 23. Neurokinin Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neurokinin Receptor Antagonists Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Neurokinin Receptor Antagonists Sales Market Share Geographic Region (2021-2026)
Table 28. Global Neurokinin Receptor Antagonists Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Neurokinin Receptor Antagonists Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Neurokinin Receptor Antagonists Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2021-2026)
Table 32. Global Neurokinin Receptor Antagonists Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Neurokinin Receptor Antagonists Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 35. Americas Neurokinin Receptor Antagonists Sales Market Share by Country (2021-2026)
Table 36. Americas Neurokinin Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 38. Americas Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 39. APAC Neurokinin Receptor Antagonists Sales by Region (2021-2026) & (K Units)
Table 40. APAC Neurokinin Receptor Antagonists Sales Market Share by Region (2021-2026)
Table 41. APAC Neurokinin Receptor Antagonists Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 43. APAC Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 44. Europe Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 45. Europe Neurokinin Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 47. Europe Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Neurokinin Receptor Antagonists
Table 53. Key Market Challenges & Risks of Neurokinin Receptor Antagonists
Table 54. Key Industry Trends of Neurokinin Receptor Antagonists
Table 55. Neurokinin Receptor Antagonists Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neurokinin Receptor Antagonists Distributors List
Table 58. Neurokinin Receptor Antagonists Customer List
Table 59. Global Neurokinin Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Neurokinin Receptor Antagonists Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Neurokinin Receptor Antagonists Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Neurokinin Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Neurokinin Receptor Antagonists Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Neurokinin Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Neurokinin Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Neurokinin Receptor Antagonists Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Neurokinin Receptor Antagonists Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Neurokinin Receptor Antagonists Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Neurokinin Receptor Antagonists Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Astellas Pharma Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 74. Astellas Pharma Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 75. Astellas Pharma Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Astellas Pharma Main Business
Table 77. Astellas Pharma Latest Developments
Table 78. Bayer Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 80. Bayer Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. Merck Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 85. Merck Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Merck Main Business
Table 87. Merck Latest Developments
Table 88. Heron Therapeutics Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 89. Heron Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 90. Heron Therapeutics Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Heron Therapeutics Main Business
Table 92. Heron Therapeutics Latest Developments
Table 93. TerSera Therapeutics Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 94. TerSera Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 95. TerSera Therapeutics Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. TerSera Therapeutics Main Business
Table 97. TerSera Therapeutics Latest Developments
Table 98. Helsinn Healthcare Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 99. Helsinn Healthcare Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 100. Helsinn Healthcare Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Helsinn Healthcare Main Business
Table 102. Helsinn Healthcare Latest Developments
Table 103. Zoetis Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 104. Zoetis Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 105. Zoetis Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Zoetis Main Business
Table 107. Zoetis Latest Developments
Table 1. Neurokinin Receptor Antagonists Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Neurokinin Receptor Antagonists Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of NK-1 Receptor Antagonists
Table 4. Major Players of NK-3 Receptor Antagonists
Table 5. Major Players of Others
Table 6. Global Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 7. Global Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Table 8. Global Neurokinin Receptor Antagonists Revenue by Type (2021-2026) & ($ million)
Table 9. Global Neurokinin Receptor Antagonists Revenue Market Share by Type (2021-2026)
Table 10. Global Neurokinin Receptor Antagonists Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Neurokinin Receptor Antagonists Sale by Application (2021-2026) & (K Units)
Table 12. Global Neurokinin Receptor Antagonists Sale Market Share by Application (2021-2026)
Table 13. Global Neurokinin Receptor Antagonists Revenue by Application (2021-2026) & ($ million)
Table 14. Global Neurokinin Receptor Antagonists Revenue Market Share by Application (2021-2026)
Table 15. Global Neurokinin Receptor Antagonists Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Neurokinin Receptor Antagonists Sales by Company (2021-2026) & (K Units)
Table 17. Global Neurokinin Receptor Antagonists Sales Market Share by Company (2021-2026)
Table 18. Global Neurokinin Receptor Antagonists Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Neurokinin Receptor Antagonists Revenue Market Share by Company (2021-2026)
Table 20. Global Neurokinin Receptor Antagonists Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Neurokinin Receptor Antagonists Producing Area Distribution and Sales Area
Table 22. Players Neurokinin Receptor Antagonists Products Offered
Table 23. Neurokinin Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neurokinin Receptor Antagonists Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Neurokinin Receptor Antagonists Sales Market Share Geographic Region (2021-2026)
Table 28. Global Neurokinin Receptor Antagonists Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Neurokinin Receptor Antagonists Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Neurokinin Receptor Antagonists Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2021-2026)
Table 32. Global Neurokinin Receptor Antagonists Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Neurokinin Receptor Antagonists Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 35. Americas Neurokinin Receptor Antagonists Sales Market Share by Country (2021-2026)
Table 36. Americas Neurokinin Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 38. Americas Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 39. APAC Neurokinin Receptor Antagonists Sales by Region (2021-2026) & (K Units)
Table 40. APAC Neurokinin Receptor Antagonists Sales Market Share by Region (2021-2026)
Table 41. APAC Neurokinin Receptor Antagonists Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 43. APAC Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 44. Europe Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 45. Europe Neurokinin Receptor Antagonists Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 47. Europe Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Neurokinin Receptor Antagonists Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Neurokinin Receptor Antagonists Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Neurokinin Receptor Antagonists Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Neurokinin Receptor Antagonists
Table 53. Key Market Challenges & Risks of Neurokinin Receptor Antagonists
Table 54. Key Industry Trends of Neurokinin Receptor Antagonists
Table 55. Neurokinin Receptor Antagonists Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neurokinin Receptor Antagonists Distributors List
Table 58. Neurokinin Receptor Antagonists Customer List
Table 59. Global Neurokinin Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Neurokinin Receptor Antagonists Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Neurokinin Receptor Antagonists Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Neurokinin Receptor Antagonists Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Neurokinin Receptor Antagonists Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Neurokinin Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Neurokinin Receptor Antagonists Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Neurokinin Receptor Antagonists Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Neurokinin Receptor Antagonists Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Neurokinin Receptor Antagonists Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Neurokinin Receptor Antagonists Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Neurokinin Receptor Antagonists Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Astellas Pharma Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 74. Astellas Pharma Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 75. Astellas Pharma Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Astellas Pharma Main Business
Table 77. Astellas Pharma Latest Developments
Table 78. Bayer Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 79. Bayer Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 80. Bayer Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Bayer Main Business
Table 82. Bayer Latest Developments
Table 83. Merck Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 85. Merck Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Merck Main Business
Table 87. Merck Latest Developments
Table 88. Heron Therapeutics Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 89. Heron Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 90. Heron Therapeutics Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Heron Therapeutics Main Business
Table 92. Heron Therapeutics Latest Developments
Table 93. TerSera Therapeutics Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 94. TerSera Therapeutics Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 95. TerSera Therapeutics Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. TerSera Therapeutics Main Business
Table 97. TerSera Therapeutics Latest Developments
Table 98. Helsinn Healthcare Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 99. Helsinn Healthcare Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 100. Helsinn Healthcare Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Helsinn Healthcare Main Business
Table 102. Helsinn Healthcare Latest Developments
Table 103. Zoetis Basic Information, Neurokinin Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
Table 104. Zoetis Neurokinin Receptor Antagonists Product Portfolios and Specifications
Table 105. Zoetis Neurokinin Receptor Antagonists Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Zoetis Main Business
Table 107. Zoetis Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neurokinin Receptor Antagonists
Figure 2. Neurokinin Receptor Antagonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurokinin Receptor Antagonists Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neurokinin Receptor Antagonists Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neurokinin Receptor Antagonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2025)
Figure 10. Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of NK-1 Receptor Antagonists
Figure 12. Product Picture of NK-3 Receptor Antagonists
Figure 13. Product Picture of Others
Figure 14. Global Neurokinin Receptor Antagonists Sales Market Share by Type in 2026
Figure 15. Global Neurokinin Receptor Antagonists Revenue Market Share by Type (2021-2026)
Figure 16. Neurokinin Receptor Antagonists Consumed in Vasomotor Symptoms
Figure 17. Global Neurokinin Receptor Antagonists Market: Vasomotor Symptoms (2021-2026) & (K Units)
Figure 18. Neurokinin Receptor Antagonists Consumed in Nausea and Vomiting
Figure 19. Global Neurokinin Receptor Antagonists Market: Nausea and Vomiting (2021-2026) & (K Units)
Figure 20. Neurokinin Receptor Antagonists Consumed in Others
Figure 21. Global Neurokinin Receptor Antagonists Market: Others (2021-2026) & (K Units)
Figure 22. Global Neurokinin Receptor Antagonists Sale Market Share by Application (2025)
Figure 23. Global Neurokinin Receptor Antagonists Revenue Market Share by Application in 2026
Figure 24. Neurokinin Receptor Antagonists Sales by Company in 2026 (K Units)
Figure 25. Global Neurokinin Receptor Antagonists Sales Market Share by Company in 2026
Figure 26. Neurokinin Receptor Antagonists Revenue by Company in 2026 ($ millions)
Figure 27. Global Neurokinin Receptor Antagonists Revenue Market Share by Company in 2026
Figure 28. Global Neurokinin Receptor Antagonists Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Neurokinin Receptor Antagonists Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 31. Americas Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 32. APAC Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 33. APAC Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 34. Europe Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 35. Europe Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 38. Americas Neurokinin Receptor Antagonists Sales Market Share by Country in 2026
Figure 39. Americas Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 40. Americas Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 41. Americas Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 42. United States Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Neurokinin Receptor Antagonists Sales Market Share by Region in 2026
Figure 47. APAC Neurokinin Receptor Antagonists Revenue Market Share by Region (2021-2026)
Figure 48. APAC Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 49. APAC Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 50. China Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 54. India Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Neurokinin Receptor Antagonists Sales Market Share by Country in 2026
Figure 58. Europe Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 59. Europe Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 60. Europe Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 61. Germany Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 62. France Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 69. Egypt Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists in 2026
Figure 75. Manufacturing Process Analysis of Neurokinin Receptor Antagonists
Figure 76. Industry Chain Structure of Neurokinin Receptor Antagonists
Figure 77. Channels of Distribution
Figure 78. Global Neurokinin Receptor Antagonists Sales Market Forecast by Region (2027-2032)
Figure 79. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Neurokinin Receptor Antagonists Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Neurokinin Receptor Antagonists Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Neurokinin Receptor Antagonists
Figure 2. Neurokinin Receptor Antagonists Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurokinin Receptor Antagonists Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Neurokinin Receptor Antagonists Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Neurokinin Receptor Antagonists Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2025)
Figure 10. Neurokinin Receptor Antagonists Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of NK-1 Receptor Antagonists
Figure 12. Product Picture of NK-3 Receptor Antagonists
Figure 13. Product Picture of Others
Figure 14. Global Neurokinin Receptor Antagonists Sales Market Share by Type in 2026
Figure 15. Global Neurokinin Receptor Antagonists Revenue Market Share by Type (2021-2026)
Figure 16. Neurokinin Receptor Antagonists Consumed in Vasomotor Symptoms
Figure 17. Global Neurokinin Receptor Antagonists Market: Vasomotor Symptoms (2021-2026) & (K Units)
Figure 18. Neurokinin Receptor Antagonists Consumed in Nausea and Vomiting
Figure 19. Global Neurokinin Receptor Antagonists Market: Nausea and Vomiting (2021-2026) & (K Units)
Figure 20. Neurokinin Receptor Antagonists Consumed in Others
Figure 21. Global Neurokinin Receptor Antagonists Market: Others (2021-2026) & (K Units)
Figure 22. Global Neurokinin Receptor Antagonists Sale Market Share by Application (2025)
Figure 23. Global Neurokinin Receptor Antagonists Revenue Market Share by Application in 2026
Figure 24. Neurokinin Receptor Antagonists Sales by Company in 2026 (K Units)
Figure 25. Global Neurokinin Receptor Antagonists Sales Market Share by Company in 2026
Figure 26. Neurokinin Receptor Antagonists Revenue by Company in 2026 ($ millions)
Figure 27. Global Neurokinin Receptor Antagonists Revenue Market Share by Company in 2026
Figure 28. Global Neurokinin Receptor Antagonists Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Neurokinin Receptor Antagonists Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 31. Americas Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 32. APAC Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 33. APAC Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 34. Europe Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 35. Europe Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Neurokinin Receptor Antagonists Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Neurokinin Receptor Antagonists Revenue 2021-2026 ($ millions)
Figure 38. Americas Neurokinin Receptor Antagonists Sales Market Share by Country in 2026
Figure 39. Americas Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 40. Americas Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 41. Americas Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 42. United States Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Neurokinin Receptor Antagonists Sales Market Share by Region in 2026
Figure 47. APAC Neurokinin Receptor Antagonists Revenue Market Share by Region (2021-2026)
Figure 48. APAC Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 49. APAC Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 50. China Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 54. India Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Neurokinin Receptor Antagonists Sales Market Share by Country in 2026
Figure 58. Europe Neurokinin Receptor Antagonists Revenue Market Share by Country (2021-2026)
Figure 59. Europe Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 60. Europe Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 61. Germany Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 62. France Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Neurokinin Receptor Antagonists Sales Market Share by Application (2021-2026)
Figure 69. Egypt Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Neurokinin Receptor Antagonists Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Neurokinin Receptor Antagonists in 2026
Figure 75. Manufacturing Process Analysis of Neurokinin Receptor Antagonists
Figure 76. Industry Chain Structure of Neurokinin Receptor Antagonists
Figure 77. Channels of Distribution
Figure 78. Global Neurokinin Receptor Antagonists Sales Market Forecast by Region (2027-2032)
Figure 79. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Neurokinin Receptor Antagonists Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Neurokinin Receptor Antagonists Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Neurokinin Receptor Antagonists Revenue Market Share Forecast by Application (2027-2032)
